Sitagliptin phosphate + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Reactive Hypoglycemia
Conditions
Reactive Hypoglycemia
Trial Timeline
Dec 1, 2008 → Mar 1, 2011
NCT ID
NCT00847080About Sitagliptin phosphate + Placebo
Sitagliptin phosphate + Placebo is a approved stage product being developed by Merck for Reactive Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00847080. Target conditions include Reactive Hypoglycemia.
What happened to similar drugs?
0 of 2 similar drugs in Reactive Hypoglycemia were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00847080 | Approved | Completed |
Competing Products
2 competing products in Reactive Hypoglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levalbuterol HCl Inhalation Solution + Levalbuterol HCl Inhalation Solution + Albuterol HCl Inhalation Solution | Sumitomo Pharma | Phase 3 | 40 |
| Rosuvastatin | AstraZeneca | Phase 3 | 32 |